This is not a knock on BD per se, but an issue the organization faces more generally. The pay is widely regarded as sub-par for the industry (ask most ex-Amgen employees if you want to confirm this), especially for the quality of employee and work that is done. The inflation adjustment for 2021 was less than half of inflation for top performers which seems to signal that management is ok with employee turnover. Also, the base pay adjustment between an average employee and a high performer won't be reflected in the base salary (although there is a high degree of spread in the bonus and stock grants).